Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics

BJU International

Volumn 104, Issue 7, 2009, Pages 1009-1016

  Dai, Bo ^a   Kong, Yun Yi ^a   Ye, Ding Wei ^a   Ma, Chun Guang ^a   Zhou, Xiaoyan ^a   Yao, Xu Dong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

4E BP1; Akt; Markers; MTOR; Prostate cancer; PTEN

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER TISSUE; CHINESE; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME ACTIVATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ORCHIECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 70049113978     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08538.x     Document Type: Article

References (31)

1. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 2008 10 : 325 331
2. Peyromaure M, Debre B, Mao K et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol 2005 174 : 1794 1797
3. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004 351 : 1488 1490
4. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 2004 31 : 26 32
5. Simons JW, Carducci MA, Mikhak B et al. Phase I /II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006 12 : 3394 3401
6. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006 24 : 419 424
7. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006 12 : 679 689
8. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006 441 : 424 430
9. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007 12 : 9 22
10. Zhou X, Tan M, Stone Hawthorne V et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004 10 : 6779 6788
11. Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007 120 : 1803 1810
12. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70, S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004 10 : 8421 8425
13. Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70, S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007 251 : 105 113
14. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 2281 (Pubitemid 46849157)
15. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005 65 : 2825 2831
16. Cao C, Subhawong T, Albert JM et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006 66 : 10040 10047
17. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007 109 : 2257 2267
18. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 2008 112 : 2352 2358
19. Thomas GV, Horvath S, Smith BL et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004 10 : 8351 8356
20. Schmitz M, Grignard G, Margue C et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007 120 : 1284 1292
21. Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006 66 : 7783 7792
22. Kremer CL, Klein RR, Mendelson J et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006 66 : 1203 1212
23. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004 10 : 594 601
24. Yoshimoto M, Cutz JC, Nuin PA et al. Interphase FISH: analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006 169 : 128 137
25. Rojo F, Najera L, Lirola J et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007 13 : 81 9
26. Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006 147 : 2557 66
27. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005 65 : 2406 2411
28. Malik SN, Brattain M, Ghosh PM et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002 8 : 1168 1171
29. Kreisberg JI, Malik SN, Prihoda TJ et al. Phosphorylation of Akt. (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004 64 : 5232 5236
30. Shimizu Y, Segawa T, Inoue T et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 2007 100 : 685 90
31. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006 19 : 238 245